|
Early Hearing Detection and Intervention
|
Meeting/ Workshop
|
CDC, HRSA
|
NIDCD
|
This is Federal collaboration program involving the National Institute on Deafness and Other Communication Disorders (NIDCD), the Centers for Disease Control and Prevention (CDC), and the Health Resources and Services Administration (HRSA). NIDCD collaborates on early identification and diagnosis of hearing loss and intervention services for newborns and infants. HRSA funds awards to states and healthcare providers to screen newborns and young children for hearing loss. CDC funds states to develop data systems to track hearing loss. NIDCD also funds research grants to scientists throughout the US to study early hearing detection and intervention services.
|
|
Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) Multisite with Coordinating Center
|
Research Initiative
|
HRSA
|
NHLBI, NICHD, NIDDK, OD/DPCPSI/OBSSR, ODP
|
To test the effectiveness of an implementation-ready intervention designed to promote cardiovascular health (CVH) and address CVH disparities in both mothers and children (0-5 yr.) who are of low socio-economic status (SES), or live in low-income underserved rural or urban communities, or in diverse geographic regions with high burden of cardiovascular disease (CVD) risk factors (obesity, hypertension, diabetes).
|
|
Ebola Clinical Research Response in Democratic Republic of the Congo
|
Research Initiative
|
CDC
|
NIAID
|
Multi-lateral collaborative partnerships including, but not limited to National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and host countries Ministeries of Health. Research focus includes Ebola and other emerging and re-emerging infectious diseases. These programs are capable of rapidly mounting a clinical research response.
|
|
Ebola Clinical Research Response in West Africa (Guinea, Liberia)
|
Research Initiative
|
CDC, FDA
|
NIAID
|
Multi-lateral collaborative partnerships including, but not limited to National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and host countries MoH. Research focus includes Ebola and other emerging and re-emerging infectious diseases. These programs are capable of rapidly mounting a clinical research response.
|
|
Ebola Vaccines Advisory Committee on Immunization Practises (ACIP) Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID
|
Develop recomendations on Ebola Vaccines for Advisory Committee on Immunization Practises (ACIP)
|
|
eCare Plan for People with Multiple Chronic Conditions Project
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CMS, FDA, HRSA, ASPE, ACL
|
NIA, NCI, NIDDK, NLM
|
To develop and test: 1) a clinician-facing SMART on FHIR e-care plan application to enable clinicians to view and share comprehensive e-care plan data for people with multiple chronic conditions and 2) an HL7 Implementation Guide (IG) to specify data standards and help healthcare institutions implement the e-care plan.
|
|
Emergency Preparedness, Medical Countermeasures
|
Resource Development
|
OS
|
NCI
|
The National Cancer Institute (NCI) provides expertise in radiation biology and radiation oncology to help guide the research and development of medical countermeasures for radiation injury and for biomarkers for assessing injury, dose, and who needs treatment.
|
|
End-stage Renal Disease Collaboration
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA
|
NIDDK, NIBIB
|
Participating agencies and patient and physician groups are collaborating to help the medical product development community to understand the challenges and milestones needed to achieve the goal of a successful alternative to dialysis. Research, regulatory, and reimbursement needs for such a product are discussed in phone calls and structured meetings.
|
|
Endocrinologic and Metabolic Drugs Advisory Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD
|
The Endocrinologic and Metabolic Drugs Advisory Committee (the Committee) advises the Commissioner or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs for human use and, as required, any other product for which the Food and Drug Administration (FDA) has regulatory responsibility.
|
|
Environmental Phthalate Exposures in Pregnancy in Relation to Fetal and Placental Development
|
Research Initiative
|
CDC
|
NIEHS
|
The purpose of this collaboration is to characterize exposure to phthalates and phthalate alternatives in pregnant women by measuring phthalate and phthalate alternative metabolites in urine samples from 8 visits in pregnancy. We will examine associations between these markers and fetal growth as well as ultrasound measures of placental development.
|